Cytotoxicity and infiltration of human NK cells in like tumor spheroids by unknown
Giannattasio et al. BMC Cancer  (2015) 15:351 
DOI 10.1186/s12885-015-1321-yTECHNICAL ADVANCE Open AccessCytotoxicity and infiltration of human NK cells in
in vivo-like tumor spheroids
Ariane Giannattasio1†, Sandra Weil1†, Stephan Kloess2, Nariman Ansari3, Ernst H K Stelzer3, Adelheid Cerwenka4,
Alexander Steinle5, Ulrike Koehl2 and Joachim Koch1*Abstract
Background: The complex cellular networks within tumors, the cytokine milieu, and tumor immune escape
mechanisms affecting infiltration and anti-tumor activity of immune cells are of great interest to understand tumor
formation and to decipher novel access points for cancer therapy. However, cellular in vitro assays, which rely on
monolayer cultures of mammalian cell lines, neglect the three-dimensional architecture of a tumor, thus limiting
their validity for the in vivo situation.
Methods: Three-dimensional in vivo-like tumor spheroid were established from human cervical carcinoma cell lines
as proof of concept to investigate infiltration and cytotoxicity of NK cells in a 96-well plate format, which is applicable
for high-throughput screening. Tumor spheroids were monitored for NK cell infiltration and cytotoxicity by flow
cytometry. Infiltrated NK cells, could be recovered by magnetic cell separation.
Results: The tumor spheroids were stable over several days with minor alterations in phenotypic appearance. The
tumor spheroids expressed high levels of cellular ligands for the natural killer (NK) group 2D receptor (NKG2D),
mediating spheroid destruction by primary human NK cells. Interestingly, destruction of a three-dimensional tumor
spheroid took much longer when compared to the parental monolayer cultures. Moreover, destruction of tumor
spheroids was accompanied by infiltration of a fraction of NK cells, which could be recovered at high purity.
Conclusion: Tumor spheroids represent a versatile in vivo-like model system to study cytotoxicity and infiltration of
immune cells in high-throughput screening. This system might proof useful for the investigation of the modulatory
potential of soluble factors and cells of the tumor microenvironment on immune cell activity as well as profiling of
patient-/donor-derived immune cells to personalize cellular immunotherapy.
Keywords: NK cell, tumor immune escape, tumor infiltration, tumor spheroid, 3D culture, innate immune system,
NKG2D, ligand sheddingBackground
Natural killer (NK) cells rapidly recognize and destroy
malignantly transformed cells [1-3]. Due to their natural
ability to lyse tumor cells without prior sensitization, NK
cells hold promise for cancer immunotherapy [4-8].
However, tumor immune escape strategies might com-
promise NK cell activity, promoting tumor formation
and progression of cancer [2]. NK cell cytotoxicity is
tightly regulated by a dynamic balance of signals from
activating and inhibitory cell surface receptors [1,9].* Correspondence: joachim.koch@gsh.uni-frankfurt.de
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unless otherwise stated.Among the major activating receptors are the NK group
2 member D receptor (NKG2D) [10-12], the natural
cytotoxicity receptors (NCR) [13-15] and DNAM-1 [16].
Human NKG2D recognizes several structurally related
ligands (NKG2DLs) on tumor cells from various cyto-
logical origin, including the MHC class I chain-related
protein A (MICA), MICB, and the UL16-binding proteins
(ULBPs) [15,17,18]. Besides their role as tumor antigens,
the ectodomains of the NKG2DLs can be shed from the
plasma membrane of malignantly transformed cells and
subsequently inhibit NKG2D-dependent NK cell cytotox-
icity [19,20]. Importantly, tumor infiltration of NK cells co-
incides with anti-tumor activity and is associated with a
better prognosis in several cancer entities such asntral. This is an Open Access article distributed under the terms of the Creative
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renal cell carcinoma [21-25]. However, NK cell cytotoxicity
might be modulated by cytokines, the cellular crosstalk
with tumor-associated cells and tumor immune escape
mechanisms within the tumor microenvironment [26].
The tumor microenvironment is comprised of malig-
nantly transformed cells, their surrounding stroma
(which consists of fibroblasts, endothelial cells, pericytes,
and mesenchymal cells), innate immune cells (including
macrophages, neutrophils, mast cells, myeloid-derived
suppressor cells, dendritic cells, and NK cells), and adap-
tive immune cells (T and B lymphocytes) [27,28]. More-
over, tumor formation is a highly dynamic process which
requires the concerted action of soluble factors and cel-
lular interactions [28]. In order to study cellular net-
works within a tumor, a model system is required that
accounts for this complexity. The majority of published
studies is based on monolayer cell culture systems,
which lack essential cellular interactions present in vivo
that are a prerequisite for polarity, differentiation and
the establishment of metabolic gradients. Furthermore,
2D cultures do not enable immunosurveillance and infil-
tration studies. Therefore, the demand to develop three-
dimensional cellular model systems is increasing [29,30].
Within the current study, we have established three-
dimensional multicellular tumor spheroids, which re-
semble many features of in vivo tumors and allow for
systematic investigation of molecular parameters in a de-
fined microenvironment. Tumor spheroid cultures pos-
sess a complex network of cell-cell contacts as well as
pH, oxygen, metabolic and proliferative gradients remin-
iscent of the conditions found in poorly vascularized and
avascular regions of solid tumors and micrometastases
[29,31-34]. Tumor spheroids are formed by association
of several thousand cells and are consequently com-
prised of an outer region of proliferating cells around a
body of quiescent cells [31,33]. Moreover, similar to the
situation found for benign tumors in vivo, tumor spher-
oids develop a necrotic core once their diameter exceeds
the requirements for efficient diffusion of oxygen, nutri-
ents, and metabolites (Figure 1A). Until now, tumor
spheroids were mainly used to assess the efficacy and
toxicity of drugs in high-throughput screening [29,30].
In the current study, we introduce 3D tumor spheroids
as tumor mimic to study NK cell infiltration and immu-
nosurveillance. As a proof of concept, we employed
tumor spheroids of two human cervical carcinoma cell
lines (SiHa: grade II, human cervix squamous cell car-
cinoma and CaSki: cervical epidermoid carcinoma). We
show that tumor spheroids allow for long-term observa-
tion of cell proliferation, NK cell infiltration and NK cell
cytotoxicity in the absence and presence of soluble me-
diators. Importantly, fluorimetric analysis enables the
quantification of anti-tumor efficacy. Moreover, magneticactivated cell sorting (MACS) allows for isolation and ana-
lysis of immune cells, which have infiltrated into the
tumor spheroids.
Based on these data, the current study shows that
tumor spheroids represent a novel tool to decipher de-
terminants of tumor immune escape and to study cellu-
lar interaction networks in 3D. Therefore, tumor
spheroids might proof useful to improve the activity of
tumor infiltrating immune cells, which might be import-
ant for donor selection of cytotoxic lymphocytes, status
quo determination of anti-tumor immunoreactivity, and
preconditioning of a cancer patient prior to (allogeneic)




Primary NK cells were purified (>95% pure) from buffy
coats of healthy donors. Buffy coats were derived from
whole-blood donations of healthy volunteer blood do-
nors kindly provided by the German Red Cross Blood
Service, Institute for Transfusion Medicine and Immuno-
hematology, Medical School, Goethe-University Frankfurt,
Germany. They were used in an anonymized fashion
with written donor approval and approval by the Ethics
Committee of Goethe University, Frankfurt, permit
#329/10. PBMCs were isolated by a density gradient
with Biocoll (Biozol, Germany) followed by indirect
magnetic immunoselection (Miltenyi Biotec, Germany)
and activation in X-Vivo10 medium (Lonza, Switzerland)
supplemented with 5% human serum (Life Technologies,
USA), 1000 IU/ml IL-2 (Promokine, Germany) and activa-
tion beads (Miltenyi Biotec, Germany) for at least
7 days. The cervical carcinoma cell lines CaSki (cervical
epidermoid carcinoma) and SiHa (grade II, human cer-
vix squamous cell carcinoma) were kindly provided by A.
Cerwenka, DKFZ, Heidelberg, Germany and cultured in
DMEM (Life Technologies, USA) basal medium supple-
mented with 10% FCS (PAA and PAN Biotech, Germany),
1% Penicillin/Streptomycin (Life Technologies, USA) and
2 mM L-Glutamine (Life Technologies, USA).
Multicellular tumor spheroids
Solid tumor spheroids were generated by seeding 5×103 –
1×104 cells/well in a volume of 150 μl/well of culture
medium in 96-well plates coated with 1.5% agarose in
basal DMEM medium. Tumor spheroids were used for
functional assays upon reaching a solid state approxi-
mately 48 h after initial seeding (d0). Growth was moni-
tored by transmission and fluorescence microscopy. For
tumor spheroid growth curves, phase contrast pictures of
independent solid spheroids were analyzed for each condi-
tion from six independent experiments by Fiji software
[35]. Tumor spheroid volume was calculated based on
Figure 1 Establishment of tumor spheroids. (A) Schematic representation of the microarchitecture of tumor spheroids, avascular tumor microregions and
developing micrometastases (based on Friedrich et al. [38]) highlighting the pathophysiological similarities and differences. On the right, representative
tumor spheroids derived from 2×103 cells are shown in a 96-well plate and by transmission microscopy at 50× magnification. (B) Growth
kinetics of cervical carcinoma tumor spheroids. 5×103 CaSki or SiHa cells were seeded, and tumor spheroid growth was monitored by phase
contrast microscopy at 50× magnification. The solid spheroidal state (day 0 = d0) was used in all further experiments as starting point. Tumor
spheroid growth is plotted as the volume of individual spheroids from six independent experiments (n = 6). Data are shown as mean ± SEM.
Spheroid volume (in mm3) was calculated based on phase contrast image analysis by area determination using Fiji software [35]. The size bar
corresponds to 100 μm. A p value < 0.05 is marked as statistically significant (*).
Giannattasio et al. BMC Cancer  (2015) 15:351 Page 3 of 13area analysis of solid spheroids by Fiji software assuming a
perfect sphere.
Flow cytometry
For the detection of NKG2DLs, single-cell suspensions
of monolayer cells or tumor spheroids treated withTrypLE™ Express (Life Technologies, USA) were stained
with mouse monoclonal antibodies: mouse anti-human
MICA (AMO1[36]), mouse anti-human MICB (MAB1599),
mouse anti-human ULBP1 (MAB1380), mouse anti-
human ULBP2 (MAB1298) and mouse anti-human
ULBP3 (MAB1517, all R&D Systems, USA). Rat anti-
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Germany) or rat anti-mouse IgG2a/b-APC (130-095-880,
Miltenyi Biotec, Germany) served as secondary antibodies.
As negative control, samples incubated with secondary
antibodies only were used. Cells were analyzed with
FlowJo software (Tree Star, USA) after measurement on a
FACS Canto II instrument equipped with a 96-well plate
HTS Sampler. Viability of cells was analyzed by SytoxBlue
stain (Life Technologies, USA). 10,000 events of viable
cells were analyzed. To calculate x-fold MFI over back-
ground, data of individual experiments (n = 3) were nor-
malized by division of the MFI by the MFI of the
secondary antibody controls to calculate mean ± SEM.
ELISA
In order to analyze shedding of NKG2DLs, supernatants
of 96 solid tumor spheroids or parental monolayer cul-
tures of counted cell culture flasks were collected at
different time points within 72 h (d0, d1, d2) and con-
centrated 10-fold using Amicon centrifugal filter units
(Merckmillipore, Germany). Soluble MICB, ULBP1 and
ULBP2 levels were quantified by DuoSet ELISA kits
(DY1599, DY1380, DY1298, R&D Systems, USA), fol-
lowing the manufacturer’s instructions. Soluble MICA
was analyzed as described [36] with slight modifications.
Soluble ULBP3 was detected with a similar protocol
[37]. Briefly, ELISA plates were coated with mouse anti-
human MICA (AMO1) or goat anti-human ULBP3 anti-
bodies (AF1517, R&D Systems, USA). After saturation
with BSA blocking solution (Candor, Germany), the
plates were incubated with either samples, recombinant
soluble MICA*04 or recombinant ULBP3-Fc (1517-UL-
050, R&D Systems, USA) as standards. For detection
and quantification of sMICA, the mouse anti-human
MICA/B antibody (BAMO3) was used in combination
with a goat anti-mouse IgG2a horseradish peroxidase-
conjugated antibody (1080–05, Southern Biotechnolo-
gies, USA). For sULBP3, the mouse anti-human ULBP3
antibody (CUMO3) was used in combination with a goat
anti-mouse IgG1 horseradish peroxidase conjugated
antibody (1070–05, Southern Biotechnologies, USA).
Following visualization with TMB substrate (KPL,
Germany), signals were measured in a microtiter plate
reader (λ = 450 nm) and analyzed with Prism 5 software
(GraphPad, USA). Data were calculated as mean ± SEM
per 10.000 cells (per spheroid) of three independent ex-
periments (n = 3), measured in duplicates.
Functional assays
For monolayer cell cytotoxicity assays CaSki and SiHa
monolayer cells were washed, dissociated from cell cul-
ture flasks, and the cell suspension was fluorescently la-
beled with CFSE (Life Technologies, USA). Labeled
target cells were incubated for 4 h with primary NK cellsat appropriate E:T ratios in NK cell medium without IL-
2. For blocking experiments, NK cells were pre-
incubated for 30 min with anti-human NKG2D blocking
mAb (MAB139, R&D Systems, USA) or anti human
TRAIL mAb (EXB-10-316, AXXORA, USA). At the
endpoint of the cytotoxicity assay, NK cells were labeled
with a mouse anti-human CD45-APC antibody (clone
5B1, Miltenyi Biotec, Germany). Live/dead cell discrim-
ination was achieved by staining with SytoxBlue (Life
Technologies, USA). 10,000 events of viable cells were
analyzed. The percentage of target cell lysis was calcu-
lated by gating on target cells (CFSE+) and analysis of
SytoxBlue+ and SytoxBlue− cells.
Cytotoxicity experiments in tumor spheroids were per-
formed according to the following timeline: i) seeding of
tumor cells and formation of tumor spheroids within
two days, ii) addition of pre-activated NK cells (d0), iii)
monitoring and documentation by light and fluorescence
microscopy (d1,d2), and iv) end-point analysis of cyto-
toxicity by flow cytometry (d1, d2). For cytotoxicity as-
says, CaSki and SiHa cells were fluorescently labeled
with CFSE (Life Technologies, USA) prior to seeding.
Upon reaching the solid spheroidal state (d0), NK cells
were added at appropriate E:T ratios to the spheroids in
NK cell medium without IL-2. Cytotoxicity and spheroid
destruction was monitored for 48 h (d1, d2) by bright-
field and fluorescence microscopy at 488 nm at 50×
magnification. For flow cytometry, single tumor spher-
oids were dissociated by TrypLETM Express-treatment.
NK cells in these single-cell suspensions were labeled
with a mouse anti-human CD45-APC antibody (Miltenyi
Biotec, Germany) prior to addition of counting beads
(BD, Germany) to calculate cell numbers according to
the manufacturer’s instructions. Live/dead cell discrimin-
ation was achieved by staining with SytoxBlue (Life
Technologies, USA). The percentage of viable cells was
calculated by evaluation of the gates for NK cells (CD45+/
SytoxBlue−), target cells (CFSE+/ SytoxBlue−), and fluores-
cent counting beads.
In order to study NK cell infiltration of tumor spher-
oids, CaSki and SiHa cells were fluorescently labeled
with CFSE (Life Technologies, USA) prior to seeding.
After reaching the solid spheroidal state, NK cells were
added to the spheroids in NK cell medium without IL-2
at an E:T ratio of 3:1 and incubated for 24 h. Viable
tumor spheroids were further analyzed by flow cytome-
try. For flow cytometry, tumor spheroids were harvested
with a cut 1000 μl-tip, pooled, and separated from the
supernatant containing the surrounding NK cells and re-
sidual target cells by centrifugation at 300xg for 10 s.
Following two washing steps in a volume of 50 ml PBS/
2% FCS, at 300xg for 1 min tumor spheroids were disso-
ciated by TrypLE™ Express-treatment for 5 min. The sin-
gle cell suspension was washed again and subjected to
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turer’s instructions (130-045-801, Miltenyi Biotec,
Germany). CD45 MACS beads were chosen for high af-
finity strong binding to all NK cell subpopulations. Cells
from the periphery of the tumor spheroids, and cells in
the flow through and elution fractions from MACS, were
analyzed by flow cytometry. Tumor spheroids without
NK cells and tumor spheroids incubated with NK cells,
which had not been submitted to MACS isolation served
as controls and were treated with the same procedure.
NK cells in the single-cell suspensions were labeled with
a mouse anti-human CD45-APC antibody (Miltenyi Bio-
tec, Germany) prior to addition of counting beads (BD,
Germany) to calculate cell numbers according to the
manufacturer’s instructions. Live/dead cell discrimin-
ation was achieved by staining with SytoxBlue (Life
Technologies, USA). The percentage of viable cells was
calculated by evaluation of the gates for NK cells (CD45+/
SytoxBlue−), target cells (CFSE+/ SytoxBlue−), and fluores-
cent counting beads (Additional file 1: Figure S3). For
tumor spheroid arrays, complete samples were analyzed
with cellular event counts between 5,000 and 30,000 cells
were analyzed with FlowJo software (Tree Star, USA) after
measurement on a FACS Canto II instrument equipped
with a 96-well plate HTS Sampler.
Statistical analysis
Statistical analyses were performed with the use of Prism
5 software (GraphPad, USA). Statistical significance of the
differences between tumor spheroid volume were calcu-
lated by the U Mann–Whitney test. A p value of < 0.05
was considered statistically significant. Data are shown as
mean ± SEM as indicated.
Results
Generation of tumor spheroid arrays
In order to investigate NK cell cytotoxicity against cer-
vical carcinoma, the cervical carcinoma cell lines CaSki
and SiHa were tested for their ability to form solid
tumor spheroids (Figure 1B). Tumor spheroid formation
was induced by seeding CaSki or SiHa cells into
agarose-coated 96-well plates. Spheroid formation was a
bi-phasic process of cell aggregation (24 h post seeding,
Figure 1B) and spheroid maturation due to cellular re-
arrangement (48 h post seeding). These mature tumor
spheroids (d0) were used as starting point for further
experiments. Notably, during the following two days
(d1, d2) cellular reorganization continued in the tumor
spheroids resulting in moderate compaction and associ-
ated significant volume reduction, which did not affect
further experiments (Figure 1B). Moreover, since the
tumor spheroids remained below a critical size of 500 –
600 μm [38], the tumor spheroids remained solid with-
out signs of central necrosis within five days. Theaverage volume of CaSki spheroids on d0, d1, and d2 was
0.070 ± 0.004 mm3, 0.042 ± 0.002 mm3, and 0.027 ±
0.001 mm3, respectively. The average volume of SiHa
spheroids on d0, d1, and d2 was 0.109 ± 0.010 mm3,
0.074 ± 0.002 mm3, and 0.034 ± 0.001 mm3, respect-
ively. Cell viability of >70% after 4 days of culture post
seeding (d2) was verified by flow cytometry and live/
dead cell analysis by means of SytoxBlue staining. In
conclusion, these data demonstrate that individual
tumor spheroids grown in parallel show little alter-
ations in size and growth kinetics and are thus perfectly
suited for further experiments.
Tumor spheroids express cellular ligands of NKG2D
A prerequisite for NK cell immunosurveillance of malig-
nantly transformed cells is the presence of tumor anti-
gens, which induce downstream signaling of activating
NK cell receptors and related cytotoxicity. In this con-
text, tumor spheroid culture may influence pathophysio-
logical stress levels and cell-cell contacts [29]. Therefore,
we examined the plasma membrane expression of the
stress-induced tumor antigens MICA, MICB, ULBP1,
ULBP2 and ULBP3 (collectively termed NKG2DLs) on
the tumor spheroids for comparison with the expression
levels found in the corresponding parental monolayer
cultures (Figure 2A, Additional file 2: Figure S1, repre-
sentative histograms Additional file 2: Figure S1B). As a
result, CaSki and SiHa cells derived from monolayer cul-
tures displayed a robust expression of MICA, ULBP2
and ULBP3 but showed only weak expression of MICB
and ULBP1. Interestingly, CaSki and SiHa cells derived
from tumor spheroid culture showed the same signature
of NKG2DL expression, however, the overall level of
NKG2DLs was decreased in tumor spheroids as demon-
strated by flow cytometry (Figure 2A, Additional file 2:
Figure S1A, B). Moreover, these results are supported by
immunohistochemistry investigating NKG2DLs’ expression
on cryosections of tumor spheroids (data not shown). Not-
ably, the plasma membrane levels of NKG2DLs decreased
over 3 days of tumor spheroid culture as a result of ligand
shedding from the plasma membrane (see below). By con-
trast, the expression level of HLA-A, −B, −C and -E was
preserved at both culture conditions (data not shown).
Tumor spheroids shed cellular ligands of NKG2D
Many cancer cells are known to release soluble NKG2D
ligands (soluble NKG2DLs) as part of a tumor immune
escape strategy [19]. Therefore, supernatants of solid
tumor spheroids were probed for the levels of soluble
MICA (sMICA), MICB (sMICB), ULBP1 (sULBP1),
ULBP2 (sULBP2) and ULBP3 (sULBP3) over three days
(d0, d1, d2) by ELISA. Due to continuous shedding, sol-
uble NKG2DLs accumulated in the supernatant of CaSki
































































































































Figure 2 Expression and shedding of ligands of the activating NK cell receptor NKG2D in tumor spheroids of cervical carcinoma. Tumor spheroids
grown from CaSki and SiHa cells were analyzed for the expression and release of soluble NKG2DLs. Tumor spheroid formation was induced by
seeding 104 cells into 1.5 % agarose-coated 96-wells. (A) Expression of NKG2DLs in tumor spheroids collected on day 0 (d0), day 1 (d1) and day 2 (d2)
analyzed by flow cytometry. Data are presented as mean ± SEM of three independent experiments (n = 3), measured in duplicates. (B) Kinetics of
soluble NKG2DL release. Supernatants of tumor spheroids were collected on three consecutive days (d0 – d2) and concentrated 10-fold. Shedding of
sMICA, sMICB, sULBP1, sULBP2 and sULBP3 was quantified by ELISA. Data are shown as mean ± SEM in pg/ml per 10.000 cells of three independent
experiments (n = 3), measured in duplicates.
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into the supernatant of tumor spheroids grown from
both cell lines within two days were sMICA (CaSki:
4.9 ± 1.7 pg/ml per 10,000 cells; SiHa: 4.2 ± 1.8 pg/ml
per 10,000 cells), sMICB (CaSki: 14.5 ± 2.2 pg/ml per
10,000 cells; SiHa: 12.4 ± 2.0 pg/ml per 10,000 cells),
and sULBP2 (CaSki: 17.6 ± 2.3 pg/ml per10,000 cells;
SiHa: 16.9 ± 2.2 pg/ml per 10,000 cells), whereas
sULBP3 was low and sULBP1 levels were below the de-
tection limit of the assay (<2 pg/ml). Notably, the kin-
etics of soluble NKG2DL release into the supernatant
parallels the loss of MICA, MICB, ULBP2 and ULBP3
from the cell surface (Figure 2A). This pattern of
sNKG2DL release is in agreement with parental monolayer
cultures (Additional file 2: Figure S1A). Since the generated
tumor spheroids display a robust NKG2DL signature, we
conclude, that the cervical carcinoma spheroids represent
a suitable model system for further NK cell studies.
Primary NK cells infiltrate and destroy tumor spheroids
The main focus of this study was to establish a 3D
tumor model to study infiltration and cytotoxicity of NKcells. The following issues were important: 1) easy to
handle set up, 2) implementation of commonly available
materials and analysis methods, and 3) applicability for
high-throughput screening. In order to monitor tumor
spheroid integrity and destruction, CaSki and SiHa cells
were labeled with CFSE, a common cell-tracer, which al-
lows for simultaneous long-term observation of cell pro-
liferation and cell migration. CFSE fluorescence was
stable for 6 days in CaSki and SiHa spheroids. To study
NK cell infiltration into tumor spheroids and NK cell
cytotoxicity, primary human NK cells (ex-vivo IL-2 pre-
activated and expanded) were added to solid tumor
spheroids grown from CaSki and SiHa cells at different
effector-to-target (E:T) ratios and co-cultured for several
days. Tumor spheroid integrity was monitored by light
and fluorescence microscopy (Figure 3). A co-culture
period of 48 h was identified as optimal end-point to
quantify NK cell cytotoxicity. During tumor spheroid
destruction, NK cells accumulated and proliferated in
the periphery of the tumor spheroid (Additional file 2:
Figure S1C). The degree of NK cell cytotoxicity was



































































Figure 3 NK cell cytotoxicity against tumor spheroids of cervical carcinoma. Tumor spheroids grown from CFSE-labeled CaSki or SiHa cells (d0)
were co-cultured with primary human NK cells at different effector-to-target (E:T) ratio for 48 h. Tumor spheroids without NK cells served as controls (CO).
(A) Tumor spheroid destruction was monitored by transmission and fluorescence microscopy at 100× magnification. Size bars correspond to 200 μm.
(B) Flow cytometric analysis of residual viable target cells. Individual tumor spheroids subjected to cytotoxicity assays with NK cells were disintegrated,
and NK cells were stained for CD45. The percentage of residual viable cells was calculated by evaluation of the gates for NK cells (CD45+/SytoxBlue−) and
target cells (CFSE+/SytoxBlue−). Dot blots show the percentage of viable target cells in individual tumor spheroids. Data are shown as mean ± SEM of a
representative experiment.
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have, by contrast to lysed target cells, not released intra-
cellular CFSE due to loss of cellular integrity (Figure 3).
Fluorescence microscopy revealed that solid tumor spher-
oids grown in the absence of NK cells were homogenously
stained whereas the overall number of viable and thus
fluorescent target cells dramatically decreased with in-
creasing E:T ratios as a result of NK cell cytotoxicity
(Figure 3A). To quantify NK cell cytotoxicity, wedeveloped a flow cytometry protocol for the analysis of
single tumor spheroids. Briefly, individual tumor spher-
oids and NK cells were transferred well-by-well into an
agarose-free 96-well plate. Following sedimentation of
the tumor spheroids by gentle centrifugation, superna-
tants were aspirated, and solid tumor spheroids were
disintegrated by enzymatic digest. Cell suspensions de-
rived from individual tumor spheroids were washed,
and the NK cells were labeled with CD45-specific
Giannattasio et al. BMC Cancer  (2015) 15:351 Page 8 of 13antibodies. In the next step, the dead-cell marker
SytoxBlue and fluorescent counting beads were added
to the 96-wells to quantify residual viable tumor cells.
Target cell lysis was quantified based on the number of
CFSE+/ CD45−/ SytoxBlue− target cells. The flow cy-
tometry analysis of single spheroids showed an E:T
dependent decrease of target cells (Figure 3B), which
correlated with the number of CFSE positive cells as
determined by fluorescence microscopy (Figure 3A).
Notably, samples were analyzed by applying a HTS-
sampler for sample loading in 96-well format. Thus,
NK cell cytotoxicity of individual spheroids can be ana-
lyzed by microscopy and flow cytometry in high-
throughput screening mode.
Infiltrated NK cells can be recovered from tumor spheroids
Infiltration of NK cells is a prerequisite for tumor spher-
oid destruction. However, in transmission microscopy,
we frequently observed that most NK cells were local-
ized in proliferation cones in the periphery of the tumor
spheroids, whereas only a small fraction of the applied
NK cells infiltrated into the tumor spheroid (Additional
file 3: Figure S2 and Video S1). To further characterize
these subpopulations of infiltrated and non-infiltrated
NK cells, we established a MACS-based protocol to
isolate and quantify infiltrated NK cells (Figure 4A).
Briefly, solid CaSki and SiHa tumor spheroids were co-
incubated with human primary NK cells at a low E:T ra-
tio (3:1) for 24 h to reduce destruction of the tumor
spheroids and to allow for infiltration studies. Solid
tumor spheroids grown in the absence of NK cells
served as negative control. Peripheral NK cells were sep-
arated from the residual solid tumor spheroids by centri-
fugation. Isolated tumor spheroids were disintegrated by
enzymatic digestion, and NK cells were recovered by
MACS isolation after specific labeling with CD45-
magnetobeads. The three resulting cell fractions are i)
peripheral non-infiltrating NK cells in the supernatant
after centrifugation (P), ii) tumor cells in the flow
through of the MACS column (F), and iii) infiltrated NK
cells recovered after elution from the MACS column (E)
(Figure 4A). Discrimination of tumor cells and NK cells
was achieved by means of CFSE fluorescence and spe-
cific labeling of the NK cells with CD45-specific anti-
bodies. SytoxBlue and fluorescent counting beads were
added to the samples to quantify infiltrated NK cells and
residual viable cells.
Flow cytometric analysis of the individual cell fractions
showed that the majority of NK cells did not infiltrate
and were detected in the periphery. Most importantly,
for further analysis, we have recovered 24.8 ± 1.2 ×104
and 30.5 ± 4.8 ×104 NK cells from the periphery and
4.2 ± 1.2 ×104 and 3.5 ± 1.3×104 infiltrated NK cells
from the elution fractions of CaSki and SiHa spheroids,respectively (Figure 4B and E). These cell numbers cor-
respond to 20.5% and 16.2% of total NK cells infiltrated
into CaSki and SiHa tumor spheroids (E and F fraction,
Figure 4B and E). The purity of recovered infiltrated
NK cells (E fraction) was very high with 96.0% and
97.1% viable NK cells for CaSki and SiHa tumor spher-
oids (E fraction contained 1.7 ± 0.3% viable and 9.7 ±
1.2% dead tumor cells for CaSki and 1.7 ± 0.7% viable
and 11.0 ± 1.5% dead tumor cells for SiHa tumor
spheroids, Figure 4D and G). Interestingly, more than
98.0% of the peripheral NK cells were viable (P frac-
tion: 80.0 ± 1.0% viable and 1.0 ± 0.0% dead NK cells
for CaSki, 80.5 ± 0.5% viable and 1.0 ± 0.0% dead NK
cells for SiHa tumor spheroids), whereas the viability
of the infiltrated NK cells was slightly lower with
82.4% and 85.4% viable NK cells derived from CaSki
and SiHa tumor spheroids (E fraction: 73.0 ± 7.4% vi-
able and 15.7 ± 7.9% dead NK cells for CaSki, 74.3 ±
6.9% viable and 12.7 ± 7.1% dead NK cells for SiHa
tumor spheroids, Figure 4C and F). Moreover, analysis
of tumor cell viability by SytoxBlue staining demon-
strated that residual viable target cells were detected in
the flow through (F fraction: 24.0 ± 8.5% viable and
23.0 ± 1.9% dead tumor cells for CaSki, 51.7 ± 1.4% vi-
able and 29.0 ± 3.2% dead tumor cells for SiHa tumor
spheroids) and also in the periphery (P fraction: 13.0 ±
1.0% viable and 6.0 ± 0.0% dead tumor cells for CaSki,
7.0 ± 0.0% viable and 11.5 ± 1.5% dead tumor cells for
SiHa tumor spheroids, Figure 4D and G). Conse-
quently tumor cells were efficiently killed by primary
NK cells after 24 h co-incubation, showing 59.9% and
45.8% dead cells for CaSki and SiHa tumor spheroids
(F fraction), respectively. For reference, tumor spher-
oids, which were grown in the absence of NK cells
showed only 26.8% and 36.3% dead tumor cells for
CaSki and SiHa tumor spheroids, respectively. Notably,
tumor spheroid destruction by NK cells was incom-
plete due to the low E:T ratio (3:1) used in these exper-
iments focused on NK cell infiltration. NK cell killing
of CaSki and SiHa cells showed a strong dependency
on the activating receptor NKG2D as demonstrated in
monolayer cytotoxicity assays in the absence and pres-
ence of NKG2D blocking antibodies (Additional file 2:
Figure S1A). In the presence of NKG2D blocking anti-
bodies killing of CaSki and SiHa cells was reduced by
55.7% and 85.1%, respectively. To address NKG2D-
dependent infiltration and cytotoxicity in the tumor
spheroid system, we used anti-NKG2D antibodies in
blocking experiments. In this context, the number of
infiltrated NK cells was reduced by 18.4% for CaSki
and by 3% for SiHa spheroids whereas NK cell viability
was not affected (data not shown). The molecular de-
tails of this phenomenon are currently not understood.





























































































Figure 4 Isolation and enrichment of infiltrated NK cells from tumor spheroids of cervical carcinoma. (A) Work flow of the cell fractionation. 96
tumor spheroids grown from CFSE-labeled CaSki or SiHa cells (d0) were co-cultured with primary human NK cells at an effector-to-target (E:T) ratio
of 3:1 for 24 h. Tumor spheroids were collected, pooled, and non-infiltrated NK cells and residual target cells in the periphery of the tumor spheroids
(P fraction) were removed by washing. Solid spheroids containing infiltrated NK cells were disintegrated and subjected to CD45 MACS-bead isolation
leading to a flow through fraction (F fraction) containing spheroid cells and an elution fraction (E fraction) containing the CD45+ NK cells. Cells from all
fractions were quantified by flow cytometry after SytoxBlue staining for discrimination of viable and dead cells. Tumor spheroids incubated in the
absence of NK cells served as cytotoxicity control (CO). (B/E) Quantification of infiltrated NK cells isolated from tumor spheroids derived from CaSki
(B) and SiHa (E) cells. Data are shown as total number of CD45+ cells per sample. (C/D/F/G) Analysis of cell viability. Proportions of viable and dead
NK cells (C/F) and target cells (D/G) within the fractions are shown. Viable cells are shown as solid bars, dead cells as open bars. Data are shown as
mean ± SEM of three individual experiments (n = 3).
Giannattasio et al. BMC Cancer  (2015) 15:351 Page 9 of 13showed that shed ligands of NKG2D might lead to ac-
tivation of NK cell cytotoxicity. Therefore, the tumor
spheroid system presented in the current study might
be helpful to characterize properties of NKG2DLs
which might only be seen in an in vivo-like situation.
Discussion
Tumor spheroids have been widely applied in investiga-
tive drug screens for chemo- and radiosensitivity [29,40]of solid cancers of epithelial origin, and their metabolic
and proliferative profiles have been well determined.
Moreover, tumor spheroids generated from CaSki and
SiHa cells were used to investigate gene expression pro-
files, calcium binding, signaling, drug metabolism and
carcinogenesis [41-47]. However, only few reports exist
employing tumor spheroids to study immunosurveil-
lance of tumor cells. In this context, previous studies
showed NK cell resistance of Ewing’s sarcoma cells that
Giannattasio et al. BMC Cancer  (2015) 15:351 Page 10 of 13were cultured in a 3D culture model [48] and PBMCs’
and γδ T cells’ activity in tumor spheroids [49,50]. In the
clinics, there is accumulating evidence that immune cell
invasion into solid tumors of different entities is an im-
portant factor for survival of patients [21,51-53] and also
for the success of cellular therapies [4]. Although NK
cells hold promise for cancer therapy, NK cell infiltra-
tion into tumors and their phenotype and function
within the tumor has not yet been extensively investi-
gated, partly due to a lack of appropriate model systems
[22-25,54-57]. Since, tumor spheroid cultures possess a
complex network of cell-cell contacts as well as pH, oxy-
gen, metabolic and proliferative gradients [29,31-33], the
model can also help to solve immunological questions of
solid tumors, which cannot be addressed in monolayer
cultures e.g. the impact of necrotic, hypoxic or hyper-
proliferative areas in tumor sites and their influence on
NK cell functions.
Here we present in vivo-like 3D tumor spheroids as a
model system for the long-term analysis of tumor immu-
nosurveillance and immune cell infiltration. The present
study is the first report investigating NK cell immuno-
surveillance at in vivo-like conditions. This novel appli-
cation of tumor spheroids enables the characterization
of infiltrating cells using commercially available reagents
and commonly used cell biological methods. Further-
more, the used 96-well plate format can easily be
adapted to high-throughput screening. Within the
current study we show an E:T ratio-dependent infiltra-
tion and destruction of tumor spheroids by primary NK
cells. Interestingly, destruction of a three-dimensional
tumor spheroid took much longer when compared to
the parental monolayer cultures, highlighting their valid-
ity for the in vivo situation. Moreover, destruction of
tumor spheroids was accompanied by infiltration of a
fraction of NK cells, which could be recovered at high
purity.
CaSki and SiHa spheroids and parental monolayer
cells expressed ligands for the activating NK cell recep-
tor NKG2D. However, sMICA, sMICB, and sULBP2
were continuously shed from the tumor spheroids reach-
ing saturation after approximately 48 h. This rapid re-
production and accumulation of soluble NKG2DLs in
the supernatant, highlights their role in tumor immune
escape [6,58]. Based on CaSki and SiHa tumor spheroids
with an average spheroid volume of 0.1 mm3, a single
CaSki spheroid of 10,000 cells releases 38.97 pg soluble
NKG2DLs and a single SiHa spheroid 35.78 pg within 5
days. Typical concentrations of soluble NKG2DLs in
cancer patients are 0.4-10 ng/ml [6]. Taking into ac-
count the blood volumes of infants (85 ml/kg) and
adults (65 ml/kg) and the serum half-life of soluble
NKG2D ligands of 6 days [59], the tumor mass required
to account for the plasma levels of soluble NKG2DLsin patients can be estimated to tumor spheres with a
diameter of 5.9 - 17.8 mm and 10.9 - 32.7 mm, respect-
ively. Notably, the required tumor mass can be scat-
tered throughout the body (e.g. micrometastases) as
tumor foci of a size below the diagnostic detection
limit. Furthermore, the calculated tumor mass might
even be smaller, since NKG2DLs could be released by
non-tumor cells under stress conditions during cancer
therapy. The panel of ligands expressed, the route of
ligand release and the local concentrations of soluble
components in a given microenvironment might differ
from patient to patient [60].
Since NK cell infiltration is the prerequisite for NK
cell function, we focus on NK cell infiltration into tumor
spheroids. We show for the first time anti-tumor efficacy
of NK cells and efficient tumor spheroid infiltration of a
small number of primary activated NK cells into tumor
spheroids grown from cervical carcinoma. We assume
that these NK cell subpopulations could be of differen-
tial phenotype in agreement with Horowitz et al. who
showed the existence of more than 6,000-30,000 pheno-
typically distinct NK cell subsets in the blood of a single
human [61,62] and with Bhat et al. who showed that NK
cells were not equally active in forming contacts and
killing targets but few ‘hyperactive’ NK cells were ob-
served in cytotoxicity assays [63]. Different factors of
immunoediting and immunoevasion could also affect
the anti-tumor activity of NK cells [26] and the cellular
crosstalk with other cells within the tumor [64,65]. Fur-
ther characterization of these isolated subpopulations
will be instrumental to decipher which factors determine
infiltration into solid tumors and will help to improve
cellular therapies of solid cancers.
Conclusions
Taken together, tumor spheroids are a more appropriate
model system for in vivo tumors than conventional
monolayer cultures and allow for stable, reproducible,
long-term co-culture with NK cells and also with other
immune cells. The presented methods offer the possibil-
ity to use the tumor spheroid model system in different
ways. Single tumor spheroids can be used i) to monitor
tumor growth, ii) to investigate immunosurveillance and
associated immune escape by soluble mediators, iii) to
investigate tumor spheroid infiltration and spheroid de-
struction, and iv) to analyze cellular interaction networks
by fluorescence microscopy and flow cytometry. Most
importantly, infiltrated NK cell subpopulations can be
quantified and characterized after isolation. In addition,
spheroids can be sectioned and stained for NK cell infil-
tration as well as for apoptosis by immunohistochemis-
try. The tumor spheroid model system and the described
methods can be adapted to many cell lines of different
solid cancer entities of epithelial origin (a comprehensive
Giannattasio et al. BMC Cancer  (2015) 15:351 Page 11 of 13list of suitable cell lines can be found at [38,66]) as well as
to different cytotoxic lymphocyte populations. Further-
more, stromal cells and other cell types that might affect
the tumor micromilieu can be included to introduce fur-
ther complexity of the tumor microenvironment.
Therefore, tumor spheroids represent a versatile
in vivo-like model system to study cytotoxicity and infil-
tration of immune cells and might proof useful for the
investigation of the modulatory potential of soluble factors
and cells of the tumor microenvironment on immune cell
activity as well as profiling of patient-/donor-derived im-
mune cells to personalize cellular immunotherapy.Additional files
Additional file 1: Figure S3. Gating strategy for flow cytometry assays.
In order to study NK cell infiltration of tumor spheroids, CaSki and SiHa
cells were fluorescently labeled with CFSE prior to seeding. After reaching
the solid spheroidal state, NK cells were added to the spheroids in NK
cell medium without IL-2 at a low E:T ratio of 3:1 and incubated for 24 h.
Viable tumor spheroids were further analyzed by flow cytometry. NK cells
in the single-cell suspensions were labeled with a mouse anti-human
CD45-APC antibody prior to addition of counting beads to calculate cell
numbers according to the manufacturer’s instructions. Live/dead cell
discrimination was achieved by staining with SytoxBlue. The event counts
of viable cells were calculated by evaluation of the gates for NK cells
(CD45+) target cells (CFSE+), and fluorescent counting beads. Cells were
analyzed on a FACS Canto II instrument with FlowJo software.
Additional file 2: Figure S1. Expression and shedding of ligands for
the activating NK cell receptor NKG2D in monolayer culture and NKG2D-
dependent cytotoxicity of NK cells against cervical carcinoma cells. (A)
NKG2DL expression levels in cervical carcinoma cell lines. CaSki and SiHa
cells grown as monolayer culture were stained for expression of NKG2DLs
and analyzed on day 0 (d0), day 1 (d1) and day 2 (d2) by flow cytometry.
Background-corrected MFI of three independent experiments (n = 3)
measured in duplicates are shown as mean ± SEM. Kinetics of soluble
NKG2DL release. Supernatants of monolayer cultures were collected on
three consecutive days (d0 – d2) and concentrated 10-fold. Shedding of
sMICA, sMICB, sULBP1, sULBP2 and sULBP3 was quantified by ELISA. Data
are shown as mean ± SEM in pg/ml per 104 cells of three independent
experiments (n = 3), measured in duplicates. NK cell cytotoxicity assays.
CaSki or SiHa cells were co-cultured with primary human NK cells for 4 h
in different E:T ratios and analyzed by flow cytometry. Target cells were
labeled with CFSE prior to seeding, and NK cells were labeled with
anti-CD45 antibodies. The degree of target cell lysis was calculated by
gating on CD45−/ CFSE+ cells and analysis of dead SytoxBlue+ or viable
SytoxBlue− cells. Specific blocking antibodies were used to determine
NKG2D- and TRAIL-dependency of NK cell cytotoxicity. Data are shown as
mean ± SEM of duplicates of a representative experiment. (B) Representative
flow cytometry histograms of CaSki and SiHa cells grown as monolayer
culture or as tumor spheroids stained for expression of NKG2DLs are shown on
day 2. (C) A representative tumor spheroid is shown after 1 h co-incubation
with primary NK cells at an effector-to-target ratio of 5:1 by phase
contrast microscopy at 50× magnification. The size bar corresponds
to 500 μm.
Additional file 3: Figure S2 and Video S1. Video sequence of tumor
spheroid infiltration by NK cell. Tumor spheroids were co-cultured in a
low effector-to-target (E:T) ratio of 2.5:1 with primary NK cells to favor
infiltration events. In order to visualize the tumor spheroids, they were
labeled with the photo-labile CFSE-dye. Therefore, disappearance of green
fluorescence within 48 h of observation results from photo-bleaching of
the CFSE-dye, rather than destruction of tumor spheroid cells. Moreover,
photo-bleaching allows for visualization of infiltrated NK cells (labeled with
photo-stabile Hoechst-red-dye) with improved contrast. Live cell imaging
was performed on a Carl Zeiss Cell Observer Spinning Disk microscope.Pictures were taken with a 10× NA 0.3 objective lens every 30 min over
48 h (representative video sequence). Pictures derived from the video
sequence (same focal plane) at different time points are shown. The
dashed line indicates the borders of the tumor spheroid from time
point 0 (Figure S2).
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